ADMA Biologics Inc (ADMA)vsargenx NV ADR (ARGX)
ADMA
ADMA Biologics Inc
$9.63
-15.00%
HEALTHCARE · Cap: $2.29B
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 730% more annual revenue ($4.24B vs $510.17M). ARGX leads profitability with a 30.5% profit margin vs 28.8%. ADMA trades at a lower P/E of 16.1x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ADMA
Buy56
out of 100
Grade: C
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-299.0%
Fair Value
$4.08
Current Price
$9.63
$5.55 premium
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 36 in profit
Strong operational efficiency at 45.1%
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Attractively priced relative to earnings
18.4% revenue growth
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Areas to Watch
Earnings declined 52.8%
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.8% and operating margin at 45.1%. Revenue growth of 18.4% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bear Case : ADMA
The primary concerns for ADMA are EPS Growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ADMA carries more volatility with a beta of 0.59 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (63/100 vs 56/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?